Draig Therapeutics Secures FDA Clearance to Launch Phase 2 Trial of DT-101 for Major Depressive Disorder

DT-101 is designed to allow effective modulation of the AMPA receptor without compromising safety Phase 2 clinical trial initiation anticipated before...

October 03, 2025 | Friday | News
George Medicines and Biolab Partner to Bring Innovative Hypertension Therapy GMRx2 to Brazil

Biolab Farmacêutica gains exclusive rights in Brazil to GMRx2, an innovative single pill combination of three medicines, including two doses that...

October 03, 2025 | Friday | News
BMS’s BMS-986446 Receives FDA Fast Track Designation for Early Alzheimer’s Therapy

Anti-microtubule binding region-tau antibody being investigated as a potential disease-modifying therapy to slow or delay progression of disease Fas...

October 02, 2025 | Thursday | News
POP Biotechnologies Secures $2.46M NIH Grant to Advance “Mosaic” Immunotherapy for Alzheimer’s

POP Biotechnologies, Inc. (POP BIO), has been awarded a $2.46M USD grant by the National Institutes of Health (NIH) to pursue development of a “mos...

October 02, 2025 | Thursday | News
Barinthus Bio and Clywedog Therapeutics Announce Definitive Merger Agreement to Create Nasdaq-Listed Clywedog Therapeutics, Inc.

The combined company, Clywedog Therapeutics, will bring a portfolio that includes three differentiated, clinical stage product candidates which are bei...

October 01, 2025 | Wednesday | News
ADvantage Therapeutics Secures $2.5M NIH Grant to Advance Alzheimer’s Candidate AD04®

ADvantage Therapeutics, Inc., a biotechnology company developing novel therapies for neurodegenerative diseases, announced it has been awarded a $2.5 mil...

September 30, 2025 | Tuesday | News
Lupin to Acquire VISUfarma from GHO Capital, Expanding Ophthalmology Footprint in Europe

Global pharma major Lupin Limited (Lupin), announced its wholly owned subsidiary, Nanomi B.V. ('Nanomi'), has signed a definitive agreement for the acquisi...

September 29, 2025 | Monday | News
AstraZeneca Launches AstraZeneca Direct to Expand Affordable Access to Medicines with Home Delivery

AstraZeneca announces the launch of AstraZeneca Direct, an online platform designed to create a simple, convenient way for eligible patients to access th...

September 29, 2025 | Monday | News
Eisai and Biogen Gain Australian Approval for LEQEMBI® in Early Alzheimer’s Disease

Eisai Co., Ltd. and Biogen Inc. announced that the Therapeutic Goods Administration (TGA) of Australia has approved LEQEMBI® (lecanemab), a humanized...

September 25, 2025 | Thursday | News
Booking Health Expands Access to Stage 4 Cancer Treatment in Germany

Booking Health, a leading medical travel facilitator, has announced the expansion of its oncology services to improve international access to advanced st...

September 25, 2025 | Thursday | News
Ncardia Launches First iPSC-Derived Non-Human Primate Cardiomyocytes for Translational Cardiac Research

-Ncardia, a leader in stem cell–based solutions for drug discovery and safety assessment,  announced the launch of Ncyte® NHP-C vCardiomyo...

September 24, 2025 | Wednesday | News
Remedium Bio and Eli Lilly Enter Multi-Target Gene Therapy Collaboration in Type 2 Diabetes and Obesity

Lifespan Vision Ventures is pleased to announce that its portfolio company, Remedium Bio, Inc. ("Remedium"), has entered into a multi-target research and...

September 24, 2025 | Wednesday | News
Rise Therapeutics Expands Oral Dendritic Cell Modulator Program into Sjögren’s Disease Following Positive RA Clinical Data

Supported by recent clinical data from the first-ever clinical study of an oral dendritic cell (DC) modulator in rheumatoid arthritis (RA), Rise Therapeu...

September 24, 2025 | Wednesday | News
Yatiri Bio Secures Gates Foundation Grant to Advance Proteomics Interoperability for Global Health

Yatiri Bio Inc.  announced it has received a grant from the Gates Foundation to launch a one-year project, Proteomics Interoperability, aimed at imp...

September 23, 2025 | Tuesday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2026 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close